SmithKline Beecham LYMErix Posts $18 Mil. In First Quarter Sales
SmithKline Beecham's Lyme disease vaccine is off to a "solid" start in the U.S., the company said.
SmithKline Beecham's Lyme disease vaccine is off to a "solid" start in the U.S., the company said.